CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Lena AnderschJosefine RadkeAnika KlausSilke SchwiebertAnnika WinklerElisa SchumannLaura GrunewaldFelix ZirngiblCarina FlemmigMichael C JensenClaudia RossigAntonia JoussenAnton HenssenAngelika EggertJohannes H SchulteAnnette KünkelePublished in: BMC cancer (2019)
Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing.